---
aliases: [RXRX, Recursion Pharmaceuticals]
---
#actor #biotech #ai #drugdiscovery #usa #public

**Recursion** — Largest AI biotech. Merged with Exscientia ($688M). 60PB proprietary data. Roche, Bayer partnerships.

---

## Why Recursion matters

| Metric | Value |
|--------|-------|
| Ticker | RXRX (Nasdaq) |
| Exscientia merger | **$688M** (2024) |
| Data library | **60+ petabytes** |
| Cash runway | ~$850M (to 2027) |
| Clinical readouts | 10 expected in 18 months |

---

## Exscientia merger

| Detail | Value |
|--------|-------|
| Announced | Aug 2024 |
| Closed | Early 2025 |
| Deal value | $688M (all-stock) |
| Ownership | Recursion 74%, Exscientia 26% |
| CEO | Chris Gibson (Recursion) |
| CSO | David Hallett (Exscientia) |

**Rationale:** Recursion (biology, target discovery) + Exscientia (chemistry, lead optimization) = end-to-end AI platform.

---

## Recursion OS platform

| Capability | Description |
|------------|-------------|
| Phenomics | Cellular imaging at scale |
| Genomics | CRISPR screening |
| Transcriptomics | Gene expression |
| Chemistry | Generative design (via Exscientia) |
| Data | 60+ PB proprietary dataset |

**Moat:** Largest proprietary biological dataset in industry.

---

## Pharma partnerships

| Partner | Focus | Status |
|---------|-------|--------|
| **Roche-Genentech** | Neuroscience, GI oncology | Active |
| **Bayer** | Undruggable oncology | Active |
| **Sanofi** | Immunology, oncology (Exscientia) | Active |
| **Merck KGaA** | Oncology, immunology (Exscientia) | Active |
| **Bristol-Myers** | Oncology (Exscientia) | Phase 1 data |

---

## Pipeline

| Program | Indication | Status |
|---------|------------|--------|
| REC-4881 | FAP (desmoid tumors) | Phase 2 |
| REC-3964 | C. difficile | Phase 1 |
| REC-994 | CCM | **Discontinued** (May 2025) |
| Exscientia programs | Multiple | Various |

**Setback:** REC-994 discontinued after long-term data didn't confirm efficacy.

---

## Data partnerships

| Partner | Data type |
|---------|-----------|
| [[Tempus]] | Clinical, genomic |
| Helix | Population genomics |
| Internal | 60PB phenomics |

---

## Financial position

| Metric | Value |
|--------|-------|
| Cash | ~$850M |
| Runway | To 2027 |
| Revenue model | Partnerships + pipeline |

---

## Investment case

**Bull:**
- Largest AI biotech post-merger
- 60PB proprietary data moat
- End-to-end platform (biology + chemistry)
- 10 clinical readouts coming
- Blue-chip partnerships (Roche, Bayer)

**Bear:**
- REC-994 failure
- No approved drugs yet
- Cash burn
- AI drug discovery unproven at scale
- Integration risk

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | RXRX |
| Exchange | Nasdaq |
| Platform | Recursion OS |
| Focus | AI drug discovery |

---

## Related

- [[AI drug discovery]] — concept
- [[Insilico Medicine]] — competitor
- [[Isomorphic Labs]] — competitor
- [[Biopharma]] — sector

---

## Sources

- [Recursion-Exscientia merger](https://ir.recursion.com/news-releases/news-release-details/recursion-and-exscientia-two-leaders-ai-drug-discovery-space)
- [Drug Discovery Trends](https://www.drugdiscoverytrends.com/recursion-and-exscientia-merge-in-688-m-deal-to-create-consolidated-ai-driven-drug-discovery-platform/)

*Created 2026-01-09*
